GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Cash-to-Debt

Next Science (Next Science) Cash-to-Debt : 9.64 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Next Science's cash to debt ratio for the quarter that ended in Dec. 2023 was 9.64.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Next Science could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Next Science's Cash-to-Debt or its related term are showing as below:

NXSCF' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.19   Med: 30.88   Max: No Debt
Current: 9.65

During the past 6 years, Next Science's highest Cash to Debt Ratio was No Debt. The lowest was 4.19. And the median was 30.88.

NXSCF's Cash-to-Debt is ranked better than
75.83% of 1051 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs NXSCF: 9.65

Next Science Cash-to-Debt Historical Data

The historical data trend for Next Science's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Next Science Cash-to-Debt Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial 35.09 53.45 26.70 4.19 9.64

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.70 8.25 4.19 0.47 9.64

Competitive Comparison of Next Science's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Next Science's Cash-to-Debt falls into.


Next Science Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Next Science's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=9.277 / (0.275 + 0.687)
=9.64

Next Science's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=9.277 / (0.275 + 0.687)
=9.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science  (OTCPK:NXSCF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Next Science Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Next Science's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (Next Science) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Cash-to-Debt
Comparable Companies
ASX:CAN ASX:LGP ASX:ANP ASX:LV1 ASX:IVX ASX:EOF ASX:MVP ASX:ECS ASX:PXS ASX:IDT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
NXS:Australia
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Website
https://www.nextscience.com
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.